Oragenics, Inc. (OGEN) AI Stock Analysis

Oragenics, Inc. is a biotechnology company developing innovative antibiotics to treat infectious diseases in the United States. Its pipeline includes vaccine candidates NT-CoV2-1, an intranasal formulation, and Terra CoV-2, an intramuscular candidate, both developed for immunity against the severe acute respiratory syndrome coronavirus. Beyond vaccines, its pipeline features LPT3-04 for weight loss and SMaRT Replacement Therapy, a topical product to prevent dental caries. Oragenics collaborates with Noachis Terra Inc. on coronavirus spike protein patent licensing, as well as with Precigen, Inc. and ILH Holdings, Inc. to develop and commercialize MU1140 and related homologs.

Revenue has contracted significantly over multiple fiscal years, declining from $1.2M in FY2015 to $37,653 in FY2023, reflecting a three-year compound annual growth rate of -68.2%. In FY2023, revenue fell 71.4%, gross margin stood at -72.7%, and operating margin was -55519.9%. Net income for FY2023 was -$20.7M, compared to -$14.3M in FY2022 and -$15.7M in FY2021, while research and development expenses reached $15.5M. For the trailing twelve months ended June 30, 2026, revenue stood at $0, with quarterly revenue growth falling 91.3% year-over-year and an operating margin of 0.0%.

As of June 30, 2026, Oragenics held $3.9M in cash and short-term investments, supporting total assets of $5.5M and shareholders' equity of $3.7M. The company reported a current ratio of 3.01. Operating cash flow was negative in recent annual periods, including -$7.3M in FY2023, yielding free cash flow of -$8.3M. In FY2025, capital expenditures were $3. Over a five-year period, the company's share count declined 36.5%.

Oragenics trades at a market capitalization of $2.0M and an enterprise value of -$3.9M. Its price-to-sales ratio of 89.3x stands well above the 4.1x median of its US-listed Healthcare peers, while its price-to-book ratio is 0.6x. The company's EV-to-EBITDA multiple is 0.2x versus the peer median of 12.0x. Over the past year through October 16, 2026, the stock fell 66.9%, compared to a 16.8% gain for the S&P 500 (SPY), and it traded 31.8% below its 200-day moving average.

One analyst covers Oragenics with a Hold rating. The mean price target is $2.00, representing an upside of 365.1% compared to the October 16, 2026 close of $0.43. For the next fiscal year, consensus models project revenue of $0 and an EPS of -$0.69, which represents expected EPS growth of 9.2%. The company beat earnings per share estimates in 2 of the last 4 quarters. Its next earnings report is scheduled for November 6, 2026.

This page is an AI-written research summary of Oragenics, Inc. (OGEN). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: OGEN income statement, OGEN balance sheet, OGEN key metrics, OGEN analyst forecast, OGEN chart. See the OGEN stock overview for the latest quote and news.